FULC
Price
$10.36
Change
+$0.11 (+1.07%)
Updated
Jan 14 closing price
Capitalization
683.45M
42 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$11.09
Change
+$0.66 (+6.33%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
2.36B
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FULC vs OCUL

Header iconFULC vs OCUL Comparison
Open Charts FULC vs OCULBanner chart's image
Fulcrum Therapeutics
Price$10.36
Change+$0.11 (+1.07%)
Volume$726.14K
Capitalization683.45M
Ocular Therapeutix
Price$11.09
Change+$0.66 (+6.33%)
Volume$242.8K
Capitalization2.36B
FULC vs OCUL Comparison Chart in %
FULC
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FULC vs. OCUL commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (FULC: $10.36 vs. OCUL: $11.07)
Brand notoriety: FULC and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 44% vs. OCUL: 209%
Market capitalization -- FULC: $683.45M vs. OCUL: $2.36B
FULC [@Biotechnology] is valued at $683.45M. OCUL’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 2 bullish TA indicator(s).

  • FULC’s TA Score: 4 bullish, 6 bearish.
  • OCUL’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, FULC is a better buy in the short-term than OCUL.

Price Growth

FULC (@Biotechnology) experienced а +3.81% price change this week, while OCUL (@Biotechnology) price change was -3.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

FULC is expected to report earnings on Feb 26, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.36B) has a higher market cap than FULC($683M). FULC YTD gains are higher at: -8.400 vs. OCUL (-14.086). FULC has higher annual earnings (EBITDA): -80.09M vs. OCUL (-233.54M). OCUL has more cash in the bank: 345M vs. FULC (201M). FULC has less debt than OCUL: FULC (7.01M) vs OCUL (77M). OCUL has higher revenues than FULC: OCUL (55.8M) vs FULC (0).
FULCOCULFULC / OCUL
Capitalization683M2.36B29%
EBITDA-80.09M-233.54M34%
Gain YTD-8.400-14.08660%
P/E RatioN/AN/A-
Revenue055.8M-
Total Cash201M345M58%
Total Debt7.01M77M9%
FUNDAMENTALS RATINGS
FULC vs OCUL: Fundamental Ratings
FULC
OCUL
OUTLOOK RATING
1..100
5750
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4763
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (27) in the null industry is in the same range as OCUL (47) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's SMR Rating (96) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's Price Growth Rating (47) in the null industry is in the same range as OCUL (63) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that FULC’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 24 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 6 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SACRX7.980.04
+0.50%
Spirit of America Real Estate Inc&Gr C
IJSTX14.77-0.01
-0.07%
VY® JPMorgan Small Cap Core Equity S2
PRCOX68.38-0.16
-0.23%
T. Rowe Price U.S. Equity Research
BRXAX18.15-0.05
-0.27%
MFS Blended Research Intl Eq A
MWOHX63.12-0.49
-0.77%
MFS Global Growth R3

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with WVE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+1.07%
WVE - FULC
55%
Loosely correlated
+2.04%
OCUL - FULC
49%
Loosely correlated
+6.14%
GPCR - FULC
49%
Loosely correlated
+8.23%
SLS - FULC
48%
Loosely correlated
-0.96%
KRRO - FULC
43%
Loosely correlated
+0.11%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with WVE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-2.43%
WVE - OCUL
56%
Loosely correlated
+2.23%
NRIX - OCUL
53%
Loosely correlated
+2.99%
KYMR - OCUL
52%
Loosely correlated
+1.42%
IDYA - OCUL
51%
Loosely correlated
-4.75%
EYPT - OCUL
50%
Loosely correlated
-0.06%
More